Industry News
Nelson appoints science journo as advisor
The Federal Health Minister, Dr Brendan Nelson, has appointed researcher turned science writer Dr Thomas Barlow as his science advisor. [ + ]
Catholics pledge $50K to adult stem cell research
Sydney's Catholic Archbishop, Dr George Pell, has promised to contribute $50,000 toward adult stem cell research, on condition that the NSW and Federal governments commit "significant money" to the research. [ + ]
Adult stem cell heart treatment trialled
Researchers at the Hunter Medical Research Institute (HMRI) have injected adult stem cells from the bone marrow of a 74-year-old man into his heart in an attempt to regenerate the blood supply. [ + ]
Prima creates new R&D role
Prima Biomed (ASX:PRR) today announced it had created a new research and development position to support its commercialisation abilities. [ + ]
Baby boomers to benefit from new research centre
Baby boomers will reap the benefits of a new medical research institute opened today at Concord Hospital, in western Sydney. [ + ]
Vic govt decision could spell fate of Amrad board
The fate of Amrad Corporation's beleaguered board could fall in the lap of Victorian Treasurer and Innovation Minister John Brumby. [ + ]
Fear, regulatory black hole block diabetes trials
Stringent guidelines and incomplete regulatory guidelines at home are forcing Australian and New Zealand biotechs offshore to test their novel diabetes treatments. But they are discovering that not everyone wants them. [ + ]
Cytopia teams with cancer research heavy-hitters
Melbourne company Cytopia has teamed with the Ludwig Institute for Cancer Research in Melbourne, the Queensland Institute of Medical Research (QIMR), and New York's Sloan-Kettering Institute for Cancer Research to develop new lead drug compounds for treatment of metastatic cancers based on the Eph receptor protein. [ + ]
Entrepreneur CEO to take BioSignal to market
Sydney start-up BioSignal has appointed a CEO, Swedish entrepreneur Michael Oredsson. [ + ]
Norwood seeks microneedle partners
Drug development and delivery company Norwood Abbey (ASX: NAL) is seeking partners to further progress its prototype microneedle. [ + ]
New GM cotton licenses approved
The Office of the Gene Technology Regulator (OGTR) has approved three new licenses to conduct field trials of genetically modified (GM) cotton. [ + ]
Leukaemia research gives Bresagen gets a decade of market exclusivity
Bresagen (ASX: BGN) has been granted a 10-year head start on the development of its anti-leukaemia drug E21R. [ + ]
Agenix antibody manufacture trial successful
Brisbane-based company Agenix has successfully manufactured 1.4g of its clot-binding humanised antibody under good laboratory practice (GLP) conditions in preparation for pre-clinical testing of its Thromboview blood clot imaging system, the company said. [ + ]
Iatia makes an auspicious ASX debut
It might not have been quite as exhilarating as his former life as a fighter pilot, but Iatia managing director Philippe Cussinet said the float of his company today was pretty exciting nonetheless. [ + ]
Nature backs away from Mexico transgenic study
Prestigious scientific journal Nature has been forced to back away from its support of a controversial study claiming that transgenic DNA sequences from GM corn contaminated native maize in Mexico. [ + ]